---
title: "Reishi Mushroom (Ganoderma lucidum) — Clinical Monograph (Vector Store Ready)"
category: "Herbal Monograph"
tags:
  - reishi
  - ganoderma lucidum
  - medicinal mushroom
  - oncology
  - immunomodulator
  - metabolic
  - hepatotoxicity
  - cyp450-interactions
  - anticoagulants
  - integrative-oncology
source: "Synthesized from peer-reviewed clinical trials and meta-analyses on Ganoderma lucidum (PubMed/PMC and Cochrane Reviews), pharmacokinetic and pharmacology studies (e.g., MDPI, ScienceDirect, Sage Journals, HerbalGram), and evidence summaries from Memorial Sloan Kettering Integrative Medicine, CancerChoices, Drugs.com, and related clinical reference sites."
date: "2025-11-14"
---

## Clinician TL;DR

- **Core role**: Reishi (*Ganoderma lucidum*) is best supported as an **adjunct** in oncology to improve immune parameters and quality of life (QoL) during chemo-/radiotherapy; evidence for **metabolic and cardiovascular benefits in humans is inconsistent** despite strong preclinical data.
- **PK/Bioavailability**: Orally administered triterpenoids (ganoderic acids) show **rapid absorption but very low systemic exposure and extensive metabolism**, with major biliary excretion; effects are likely mediated by **metabolites and gut-local actions**.
- **Benefits (human data)**:
  - Oncology: ↑ CD3+, CD4+, CD8+ T cells; improved QoL scores; possible but **not statistically significant** increase in tumor response when added to standard therapy.
  - Metabolic/CV: Large RCT/meta-analytic data in T2DM show **no meaningful benefit** on HbA1c, lipids, BMI, or BP; isolated trials show modest lipid improvements with spore oil or Lingzhi extracts.
- **Key risks**:
  - **Hepatotoxicity**: Rare but severe liver injury (including fatal fulminant hepatitis) reported with powdered Reishi.
  - **Bleeding/INR elevation**: Case of INR 6.9–8.2 in a patient on warfarin taking Reishi; in vitro inhibition of platelet aggregation.
  - **CYP450 inhibition**: Potent inhibition of **CYP1A2, 2B6, 2C9, 2C19, 3A4, 2D6, 2E1** by triterpenoids → risk for elevated levels of narrow-index drugs.
  - **Immune stimulation**: Theoretical antagonism of immunosuppressant drugs.
  - **Tumor marker CA72-4 elevation** with spore powder in GI cancers, confounding monitoring.
- **Avoid / use great caution**: Patients on **warfarin/anticoagulants/antiplatelets**, those with **pre-existing liver disease**, transplant or autoimmune patients on **immunosuppressants**, perioperative patients, pregnancy, lactation, and children (limited data).
- **Practical use**: If used, prefer **standardized extract** with known triterpenoid/polysaccharide content, adjunct to conventional cancer care, with **baseline and periodic labs** (LFTs, coagulation where indicated) and careful medication review.

---

## Key Clinical Indications & Evidence

### Oncology (Adjunctive Therapy)

- **Overall evidence quality**:
  - Multiple **RCTs**, and meta-analyses (including **Cochrane**), evaluate Reishi as an adjunct to chemo-/radiotherapy.
  - Evidence supports **immunologic and QoL benefits**; evidence for **tumor shrinkage or survival benefit** is **insufficient**.

- **Tumor response and survival**
  - Meta-analysis data: Adding Reishi to standard cancer therapy associated with **higher tumor response rate**, but this **did not reach statistical significance**:
    - **RR ~1.50; 95% CI 0.90–2.51**.
  - No trials demonstrate Reishi as effective **monotherapy** for tumor shrinkage.
  - **Cochrane review conclusion**: Insufficient evidence to recommend Reishi as **first-line cancer treatment**; no robust data on **long-term survival**.

- **Immune function**
  - Adjunctive Reishi led to statistically significant increases in T-lymphocyte subsets:
    - **CD3+ ↑ ~3.9%** (95% CI ≈ 1.9–5.9).
    - **CD4+ ↑ ~3.0%** (95% CI ≈ 1.0–5.1).
    - **CD8+ ↑ ~2.0%** (95% CI ≈ 0.2–3.8).
  - Interpreted as **partial reversal of chemo-induced immunosuppression**.

- **Quality of life (QoL)**
  - Across RCTs, **4/5 trials** reported improved QoL with Reishi adjunct.
  - Meta-analysis: **RR ~2.51; 95% CI 1.86–3.40** for improved QoL versus control.
  - In a trial of breast cancer patients on endocrine therapy:
    - Reishi **spore powder 1000 mg TID × 4 weeks**:
      - Improved **physical well-being**.
      - Reduced **anxiety and depression**.
      - Lowered **TNF-α and IL-6**.

- **Clinical translation**
  - Most appropriate as **adjunct** to conventional therapy to:
    - Support immune function.
    - Improve QoL and symptom burden.
  - Should **not** be positioned as an alternative to standard oncologic care.

### Metabolic, Cardiovascular & Liver Health

- **Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (preclinical)**
  - Ganoderma lucidum polysaccharides (GLPs) in animal models:
    - Improve NAFLD by **modulating gut microbiota** and **metabolic signaling pathways**.
    - Reduce hepatic steatosis and inflammatory markers.
  - These findings have **not translated consistently** into human metabolic outcomes.

- **Type 2 diabetes & cardiometabolic risk (human)**
  - Pooled analysis/meta-analysis of **17 RCTs (~971 participants)** with overall **“very low” evidence quality**:
    - **No clinically or statistically significant effects** on:
      - HbA1c
      - Total cholesterol
      - LDL-C
      - BMI
      - Blood pressure
      - Triglycerides
  - A second meta-analysis of **23 RCTs** similarly found **no significant improvement** in cardiovascular risk factors in T2DM.

- **Isolated positive trials**
  - Dyslipidemia: **Reishi spore oil 3 g/day**:
    - ↓ Total cholesterol, LDL, triglycerides.
    - ↑ HDL cholesterol.
  - Borderline hypertensive/hyperlipidemic patients:
    - **Lingzhi extract 1.44 g/day**:
      - ↑ HDL-cholesterol by ~24%.
      - ↓ Triglycerides by ~8%.
  - These findings are **not consistent** across the broader evidence base.

- **Wound healing (preclinical)**
  - Topical **Ganoderma lucidum spore oil (GLSO)** in murine burn models:
    - Accelerates **wound closure**.
    - Enhances **keratinocyte proliferation and migration**.
    - Improves **collagen deposition**.
    - Favors skin microbiota and cytokine profiles associated with healing.
  - Human clinical data for wound healing are **not yet available**.

### Urologic Symptoms

- In men with **lower urinary tract symptoms (LUTS)**:
  - An **ethanol extract of Reishi at 6 mg/day** showed benefit in at least one clinical trial.
  - Mechanism likely involves **anti-inflammatory and/or hormonal modulation**, though specific pathways were not detailed.

---

## Pharmacokinetics (ADME) & Bioavailability

- **Human data (ganoderic acids A & F)**
  - Oral **3,000 mg granular extract**:
    - **Tmax** ≈ 0.5–0.6 hours for ganoderic acids A (GA) and F (GF).
    - **Cmax**:
      - GA: ~11 ng/mL.
      - GF: ~2.6 ng/mL.
    - **AUC**:
      - GA: ~10.5 ng·h/mL.
      - GF: ~2.4 ng·h/mL.
  - Interpretation: **rapid absorption but very low systemic exposure** → **poor oral bioavailability**, likely due to:
    - Extensive **hepatic first-pass metabolism**.
    - **Intestinal bacterial conversion**.

- **Effect of food**
  - Co-administration with a meal:
    - **↓ Cmax of ganoderic acid A by >65%**.
    - Ganoderic acid F became **undetectable** in most subjects.
  - Suggests that **fasting administration** may maximize systemic exposure, but overall exposure remains low.

- **Animal data (rats, triterpenoids from spores and enriched fractions)**
  - Sporoderm-removed spore powder:
    - **Tmax range** for 12 triterpenoids: **0.25–2.33 hours**.
    - **Cmax** range: ~43–643 ng/mL.
    - **AUC** range: ~73–943 ng·h/mL.
    - Rapid and extensive distribution to **liver, lung, spleen, kidney, heart, GI tract**.
  - Triterpenoid-enriched GA-H fraction:
    - GA-H: **Tmax ~1 hour**, **Cmax ~2500 ng/mL**, **AUC ~9800 ng·h/mL** at studied doses.

- **Metabolism & elimination**
  - Extensive phase I and II metabolism:
    - Oxidation, hydroxylation, reduction, sulfation, glucuronidation.
  - Low-polarity ganoderic acids → **high-polarity metabolites**.
  - Major elimination via **biliary excretion**.

- **Clinical relevance**
  - Systemic effects are likely due to:
    - Combined action of **parent triterpenoids + metabolites**.
    - **Gut-local immunomodulation and microbiome effects**.
  - For **herb–drug interactions**, even low systemic levels can be important because **CYP inhibition potency** can be high.

---

## Dosing, Administration & Formulations

> Doses reflect ranges used in clinical trials and traditional practice; individualize and integrate with conventional care.

- **Traditional/empirical ranges**
  - **General wellness/maintenance**: ~**0.5–1 g/day** of Reishi (usually dried mushroom or extract).
  - **Chronic illness**: commonly **2–5 g/day**.
  - **Serious illness**: up to **15 g/day** reported in traditional contexts.

- **Oncology (adjunct)**
  - **Polysaccharide-rich extracts (e.g., Ganopoly)**:
    - **1800 mg TID** (total **5.4 g/day**) for **8–12 weeks** in several trials.
  - **Reishi spore powder**:
    - **1000 mg TID (3 g/day)** for **4 weeks** in breast cancer patients on endocrine therapy.

- **Metabolic/cardiometabolic**
  - Trials in T2DM/metabolic syndrome:
    - **1.4–3 g/day** of Reishi extract for **12–16 weeks**.
  - Dyslipidemia:
    - **3 g/day spore oil** showed lipid improvements in one trial.
  - Borderline hypertensive/hyperlipidemic:
    - **1.44 g/day Lingzhi extract** improved HDL (+24%) and reduced TG (~−8%).

- **Urologic symptoms (LUTS)**
  - Ethanol extract dose of **6 mg/day** demonstrated benefit in at least one trial.

- **Topical wound healing (preclinical)**
  - In vitro: Reishi mycelium extract at **5 μg/mL** enhanced keratinocyte function.
  - In vivo murine models: topical formulations often used **dilutions around 1:200** of extract.

- **Formulation considerations**
  - **Fruit body vs. spore vs. mycelium**:
    - Spores and their oils often **concentrate triterpenoids**.
    - Water extracts are **polysaccharide-rich** (β-glucans).
  - **Extraction methods**:
    - **Hot water**: preserves β-(1→3)-glucans → immunomodulatory focus.
    - **Ethanol/supercritical CO₂**: enrich triterpenoids → anti-inflammatory, hepatoprotective, and interaction-relevant fractions.

---

## Safety Profile & Toxicology

### General Tolerability

- Across clinical trials (up to **3 g/day for 10–16 weeks**):
  - Reishi is generally **well-tolerated**.
  - Common adverse events: **nausea, insomnia, dizziness, dry mouth, dyspepsia, diarrhea or constipation**.
  - In RCTs, adverse events occurred somewhat more often in Reishi vs control (**RR ~1.67** in one analysis), but:
    - No significant **hematologic** or **hepatologic** toxicity in most trials.
    - Routine labs typically remained within normal ranges.
- Animal data:
  - Very high **maximum tolerated dose (>20 g/kg)** in mice, indicating a **wide acute safety margin**.

### Serious and Rare Risks

- **Hepatotoxicity**
  - Case reports, including **one fatal case of fulminant hepatitis**, linked to **Reishi powder**.
  - EASL guidelines classify Reishi as a **potential cause of drug-induced liver injury**.
  - Practical implications:
    - **Avoid or use extreme caution** in patients with **pre-existing liver disease**.
    - Consider **baseline and periodic liver function tests (LFTs)**.
    - Advise patients to stop and seek care for **jaundice, dark urine, unexplained fatigue, RUQ pain**.

- **Bleeding and coagulopathy**
  - Reishi extracts **inhibit platelet aggregation in vitro**.
  - Case report: hemodialysis patient on **warfarin** taking Reishi extract (2 × 500 mg tablets) had **INR 6.92 and 8.22**; INR normalized after stopping Reishi.
  - Clinical guidance:
    - Avoid in patients on **warfarin or other anticoagulants/antiplatelets** unless closely supervised.
    - Avoid in patients with **bleeding disorders** or high bleeding risk.
    - Discontinue at least **2 weeks pre-operatively**.

- **Tumor marker interference**
  - Reishi **spore powder** has been associated with **elevated CA72-4** in GI cancer patients.
  - Risk: falsely suggesting **disease progression** or altering perceived treatment response.
  - Clinicians should **document Reishi use** and interpret CA72-4 trends accordingly.

- **Immune modulation**
  - Given immune-stimulating properties:
    - Theoretically **counteracts immunosuppressant drugs**.
    - **Contraindicated or strongly discouraged** in:
      - **Transplant recipients**.
      - Patients with **autoimmune conditions** on immune-suppressive regimens.

- **Special populations**
  - **Pregnancy and lactation**: insufficient safety data → recommend **avoidance**.
  - **Children**: limited data → avoid or restrict to research settings.
  - **Hypersensitivity**: discontinue with any **allergic symptoms** (rash, pruritus, dyspnea).

---

## Herb–Drug & Herb–Supplement Interactions

### Coagulation & Antithrombotic Therapy

- **Mechanism**
  - Reishi polysaccharides and other constituents **inhibit platelet aggregation**.
  - Clinical case: marked **INR elevation (up to >8)** in a patient on **warfarin** taking Reishi extract.

- **High-risk combinations**
  - **Warfarin and other vitamin K antagonists**.
  - **DOACs** (apixaban, rivaroxaban, etc.).
  - **Antiplatelets**: aspirin, clopidogrel, prasugrel, ticagrelor.
  - **Heparins and LMWH**.

- **Clinical actions**
  - Prefer **avoiding** Reishi in patients requiring **therapeutic anticoagulation or dual antiplatelet therapy**.
  - If use is unavoidable:
    - Coordinate with prescribing specialist.
    - **Increase frequency of INR and bleeding surveillance**.
    - Educate patients about signs of bleeding (bruising, hematuria, melena, epistaxis).

### CYP450-Mediated Interactions

- **Enzyme targets**
  - Dichloromethane extracts and specific triterpenoids **strongly inhibit** multiple CYP subtypes:
    - **CYP1A2, 2B6, 2C9, 2C19, 3A4**.
    - Ganoderic acid A also **inhibits CYP2D6, 2E1** (non-competitive for 3A4; competitive for 2D6/2E1).

- **In vivo findings (rat models)**
  - Co-administration with Reishi extract:
    - **Midazolam (CYP3A4 substrate)**: **AUC ↑ ~73%**.
    - **Diclofenac (CYP2C9 substrate)**: **AUC ↑ ~38%**.

- **Impacted drug classes (examples)**
  - **CYP3A4**:
    - Many **statins**, some calcium channel blockers, certain chemotherapeutics, some benzodiazepines, and targeted oral agents.
  - **CYP2C9**:
    - Warfarin, some NSAIDs (e.g., diclofenac).
  - **CYP2D6**:
    - Many antidepressants, antipsychotics, some opioids.
  - **CYP2B6**:
    - Bupropion and others.

- **Clinical approach**
  - Treat Reishi, especially **triterpenoid-rich extracts/spore oils**, as a **broad CYP inhibitor**.
  - Avoid initiating Reishi in patients on **narrow therapeutic index drugs** that depend on these pathways.
  - If benefits are judged worth the risk:
    - Consider **dose adjustments**, **therapeutic drug monitoring**, or **alternative agents** with safer interaction profiles.

### Immunologic & Pharmacodynamic Interactions

- **Immunosuppressants**
  - Theoretical antagonism of drugs like:
    - **Calcineurin inhibitors**, **mTOR inhibitors**, **mycophenolate**, systemic corticosteroids used for suppression.
  - Strongly discourage Reishi in **transplant recipients** and patients on chronic **immunosuppressive therapy**.

- **Oncologic agents**
  - Concern (theoretical) that antioxidant effects could interfere with **ROS-dependent chemotherapeutics**.
  - No conclusive human data provided, but caution is advised; coordinate with oncology when patients wish to use Reishi.

---

## Red Flags & Triage Parameters

- **Immediate discontinuation and urgent evaluation**
  - New-onset **jaundice, dark urine, pale stools, marked fatigue, RUQ pain** → evaluate for **drug-induced liver injury**.
  - Signs of **active bleeding** (hematochezia, melena, hematuria, persistent epistaxis, unexplained bruising) especially in patients on anticoagulants.
  - Acute **neurologic changes** or hemodynamic instability in anticoagulated patients (possible intracranial or internal bleeding).

- **High-risk patients (avoid or specialist-supervised only)**
  - **Moderate–severe hepatic impairment** or history of unexplained hepatitis.
  - **Transplant recipients** or patients with **autoimmune disease** requiring immunosuppression.
  - Patients on **warfarin or multiple antithrombotics**.
  - Patients with **active GI cancers** monitored with **CA72-4**, unless oncology is fully aware and in agreement.
  - Planned surgery within **2 weeks**.
  - **Pregnancy, lactation, and pediatric** populations.

- **Monitoring suggestions (when Reishi is used despite risks)**
  - Baseline and periodic:
    - **LFTs**.
    - **INR/other coagulation parameters** where anticoagulants are used.
    - Relevant **tumor markers** (e.g., CA72-4) with annotation of Reishi use.
  - Medication review for **CYP substrates** and narrow-index drugs at every visit.

---

## Quality Control, Standardization & Adulteration

- **Variability in commercial products**
  - Content of key bioactives (**triterpenoids, polysaccharides**) varies widely by:
    - Species/strain, cultivation substrate, environment.
    - Part used (fruiting body vs spore vs mycelium).
    - Extraction and drying methods.
  - Analyses of products have found:
    - Triterpene content from **undetectable to ~7.8%**.
    - Polysaccharide content roughly **1.1–5.8%**.

- **Analytical methods & markers**
  - **HPLC/UPLC** quantify specific triterpenoids (e.g., **ganoderic acid H**).
  - **LC-MS/MS** for multi-triterpenoid profiles in plasma/tissues.
  - Polysaccharides:
    - Quantified via **colorimetric assays** or **HPLC** after hydrolysis.
  - Example standards:
    - Triterpenoid-enriched fraction standardized to **23.9% GA-H w/w** via validated UPLC method.
    - Water extract quantified for total GA and GF (~1400 μg/g GA; ~220 μg/g GF).

- **Standardization strategies**
  - Many manufacturers standardize to:
    - **Total triterpenoids** (%).
    - **Total polysaccharides** (%).
  - No universal consensus standards; labels may not be directly comparable between brands.

- **Practical clinical advice**
  - Prefer products that:
    - Clearly state **species** (*G. lucidum* vs other Ganoderma).
    - Specify **part used** (fruiting body, spore, mycelium).
    - Provide **standardized percentages** of triterpenoids and/or polysaccharides.
    - Offer **quality certifications** and testing for contaminants.
  - Recognize that **spore oils and triterpenoid-enriched extracts** may carry **higher interaction risk** due to higher triterpenoid content.

---

## Practical Clinical Decision Rules (IF/THEN/BECAUSE)

- **IF** a patient with solid tumor malignancy on chemo-/radiotherapy requests Reishi for immune support and QoL,  
  **THEN** consider a **standardized polysaccharide-rich extract** adjunct for a **defined trial period (e.g., 8–12 weeks)** with clear communication that it is not a substitute for conventional therapy,  
  **BECAUSE** RCTs and meta-analyses show **improved T-cell subsets and QoL** without proven survival benefit.

- **IF** a patient is taking **warfarin or other high-risk anticoagulants/antiplatelets**,  
  **THEN** generally **advise against Reishi**, or only allow use with **close INR monitoring and specialist involvement**,  
  **BECAUSE** case reports document **INR >8** and the herb exhibits **antiplatelet activity**.

- **IF** a patient with a history of **unexplained hepatitis or chronic liver disease** is using or considering Reishi,  
  **THEN** discourage use or, at minimum, arrange **baseline and periodic LFTs** and coordinate with hepatology,  
  **BECAUSE** rare but severe cases of **Reishi-associated hepatotoxicity** have been reported and it is recognized as a possible hepatotoxin.

- **IF** a transplant recipient or patient on **immunosuppressive therapy** asks about Reishi,  
  **THEN** recommend **against its use**,  
  **BECAUSE** its **immune-stimulant properties** may counteract necessary immunosuppression.

- **IF** a GI cancer patient monitored with **CA72-4** is taking Reishi (especially spore powder),  
  **THEN** document this clearly and ensure oncology is aware,  
  **BECAUSE** Reishi can **artificially elevate CA72-4**, complicating interpretation of disease status.

- **IF** a patient on multiple CYP-metabolized medications requests Reishi,  
  **THEN** perform a **drug–interaction review** and avoid Reishi when narrow-index CYP substrates are present,  
  **BECAUSE** Reishi triterpenoids can **inhibit CYP1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and 2E1**, increasing drug exposure.

---

## High-Yield Evidence Pointers (for Retrieval)

- **Oncology adjunct, immune/QoL**
  - Meta-analyses and RCTs showing:
    - **RR ~1.50 (NS)** for tumor response.
    - **CD3+/CD4+/CD8+ T-cell increases** (~2–4% absolute).
    - **QoL RR ~2.5** in favor of Reishi adjunct.
  - Breast cancer endocrine therapy trial:
    - **Reishi spore powder 1000 mg TID × 4 weeks** → improved physical well-being, reduced anxiety/depression, ↓ TNF-α and IL-6.

- **Metabolic neutrality (human) vs benefit (animal)**
  - **17-RCT meta-analysis (~971 participants)** and **23-RCT meta-analysis** in T2DM:
    - No meaningful changes in **HbA1c, lipids, BMI, BP**.
  - Isolated trials:
    - **3 g/day spore oil** → improved lipid profile.
    - **1.44 g/day Lingzhi extract** → ↑ HDL ~24%, ↓ TG ~8%.
  - Animal models: Reishi extract improves **body weight, adiposity, lipids, insulin sensitivity, and adipokines** in high-fat diet-induced obesity.

- **PK/ADME**
  - Human: 3 g granular extract → **Tmax ~0.5–0.6 h**, low **Cmax and AUC** for GA and GF, food substantially reduces exposure.
  - Rats: sporoderm-removed spore powder → **rapid multi-organ distribution**, extensive metabolism, **biliary excretion**.

- **Safety & interactions**
  - **Hepatotoxicity**: rare cases including **fatal fulminant hepatitis**.
  - **Coagulation**: INR elevation >8 with warfarin; platelet inhibition.
  - **CYP inhibition**: broad inhibition of **CYP1A2, 2B6, 2C9, 2C19, 3A4, 2D6, 2E1** with substantial ↑ in AUC of probe substrates in animal models.
  - **Tumor marker CA72-4 elevation** with spore powder.


